STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentationsSTOUGHTON, Mass., Aug.
Last week, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright…
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $1.45 by 77.24 percent. This is a 22.22 percent increase over earnings of $0.27 per
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $1.45 by 110.34 percent. This is a 155.56 percent decrease over earnings of $0.27 per
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.